Literature DB >> 23798014

Neuropsychological outcomes in fatty acid oxidation disorders: 85 cases detected by newborn screening.

Susan E Waisbren1, Yuval Landau, Jenna Wilson, Jerry Vockley.   

Abstract

Mitochondrial fatty acid oxidation disorders include conditions in which the transport of activated acyl-Coenzyme A (CoA) into the mitochondria or utilization of these substrates is disrupted or blocked. This results in a deficit in the conversion of fat into energy. Most patients with fatty acid oxidation defects are now identified through newborn screening by tandem mass spectrometry. With earlier identification and preventative treatments, mortality and morbidity rates have improved. However, in the absence of severe health and neurological effects from these disorders, subtle developmental delays or neuropsychological deficits have been noted. Medical records were reviewed to identify outcomes in 85 children with FAOD's diagnosed through newborn screening and followed at one metabolic center. Overall, 54% of these children identified through newborn screening experienced developmental challenges. Speech delay or relative weakness in language was noted in 26 children (31%) and motor delays were noted in 24 children (29%). The majority of the 46 children receiving psychological evaluations performed well within the average range, with only 11% scoring <85 on developmental or intelligence tests. These results highlight the importance of screening children with fatty acid oxidation disorders to identify those with language, motor, or cognitive delay. Although expanded newborn screening dramatically changes the health and developmental outcomes in many children with fatty acid oxidation disorders, it also complicates the interpretation of biochemical and molecular findings and raises questions about the effectiveness or necessity of treatment in a large number of cases. Only by systematically evaluating developmental and neuropsychological outcomes using standardized methods will the true implications of newborn screening, laboratory results, and treatments for neurocognitive outcome in these disorders become clear.
Copyright © 2013 Wiley Periodicals, Inc., a Wiley company.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23798014      PMCID: PMC4137760          DOI: 10.1002/ddrr.1119

Source DB:  PubMed          Journal:  Dev Disabil Res Rev        ISSN: 1940-5529


  37 in total

1.  Short-chain acyl-CoA dehydrogenase deficiency associated with early onset severe axonal neuropathy.

Authors:  M A Kurian; L Hartley; Z Zolkipli; M A Little; D Costigan; E R Naughten; S Olpin; F Muntoni; M D King
Journal:  Neuropediatrics       Date:  2004-10       Impact factor: 1.947

2.  Short-chain acyl-CoA dehydrogenase deficiency in a 16-year-old girl with severe muscle wasting and scoliosis.

Authors:  K E Baerlocher; B Steinmann; A Aguzzi; S Krähenbühl; C R Roe; C Vianey-Saban
Journal:  J Inherit Metab Dis       Date:  1997-07       Impact factor: 4.982

3.  Genetic deficiency of short-chain acyl-coenzyme A dehydrogenase in cultured fibroblasts from a patient with muscle carnitine deficiency and severe skeletal muscle weakness.

Authors:  P M Coates; D E Hale; G Finocchiaro; K Tanaka; S C Winter
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

4.  Neonatal screening for defects of the mitochondrial trifunctional protein.

Authors:  Johannes Sander; Stefanie Sander; Ulrike Steuerwald; Nils Janzen; Michael Peter; Ronald J A Wanders; Iris Marquardt; G Christoph Korenke; Anibh M Das
Journal:  Mol Genet Metab       Date:  2005-03-24       Impact factor: 4.797

5.  Rare disorders of metabolism with elevated butyryl- and isobutyryl-carnitine detected by tandem mass spectrometry newborn screening.

Authors:  Dwight D Koeberl; Sarah P Young; Niels S Gregersen; Jerry Vockley; Wendy E Smith; Daniel Kelly Benjamin; Yan An; Susan D Weavil; Shu H Chaing; Deeksha Bali; Marie T McDonald; Priya S Kishnani; Y-T Chen; David S Millington
Journal:  Pediatr Res       Date:  2003-05-07       Impact factor: 3.756

6.  Reversal of severe hypertrophic cardiomyopathy and excellent neuropsychologic outcome in very-long-chain acyl-coenzyme A dehydrogenase deficiency.

Authors:  G F Cox; M Souri; T Aoyama; S Rockenmacher; L Varvogli; F Rohr; T Hashimoto; M S Korson
Journal:  J Pediatr       Date:  1998-08       Impact factor: 4.406

7.  Medium-chain acyl-coenzyme A dehydrogenase deficiency: clinical course in 120 affected children.

Authors:  A K Iafolla; R J Thompson; C R Roe
Journal:  J Pediatr       Date:  1994-03       Impact factor: 4.406

8.  Timing is everything: executive functions in children exposed to elevated levels of phenylalanine.

Authors:  Kevin M Antshel; Susan E Waisbren
Journal:  Neuropsychology       Date:  2003-07       Impact factor: 3.295

9.  Short-chain acyl-coenzyme A dehydrogenase deficiency. Clinical and biochemical studies in two patients.

Authors:  B A Amendt; C Greene; L Sweetman; J Cloherty; V Shih; A Moon; L Teel; W J Rhead
Journal:  J Clin Invest       Date:  1987-05       Impact factor: 14.808

Review 10.  Disorders of mitochondrial long-chain fatty acid oxidation.

Authors:  R J Pollitt
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

View more
  12 in total

Review 1.  Developmental Support for Infants With Genetic Disorders.

Authors:  Monica H Wojcik; Jane E Stewart; Susan E Waisbren; Jonathan S Litt
Journal:  Pediatrics       Date:  2020-05       Impact factor: 7.124

Review 2.  The neural stem cell/carnitine malnutrition hypothesis: new prospects for effective reduction of autism risk?

Authors:  Vytas A Bankaitis; Zhigang Xie
Journal:  J Biol Chem       Date:  2019-11-07       Impact factor: 5.157

3.  A Subset of Patients With Autism Spectrum Disorders Show a Distinctive Metabolic Profile by Dried Blood Spot Analyses.

Authors:  Rita Barone; Salvatore Alaimo; Marianna Messina; Alfredo Pulvirenti; Jean Bastin; Alfredo Ferro; Richard E Frye; Renata Rizzo
Journal:  Front Psychiatry       Date:  2018-12-07       Impact factor: 4.157

4.  Long-term outcome of expanded newborn screening at Boston children's hospital: benefits and challenges in defining true disease.

Authors:  Yuval E Landau; Susan E Waisbren; Lawrence M A Chan; Harvey L Levy
Journal:  J Inherit Metab Dis       Date:  2017-01-04       Impact factor: 4.982

5.  Assessing Psychological Functioning in Metabolic Disorders: Validation of the Adaptive Behavior Assessment System, Second Edition (ABAS-II), and the Behavior Rating Inventory of Executive Function (BRIEF) for Identification of Individuals at Risk.

Authors:  Susan E Waisbren; Jianping He; Robert McCarter
Journal:  JIMD Rep       Date:  2015-02-25

6.  Acylcarnitine Profiles in HIV-Exposed, Uninfected Neonates in the United States.

Authors:  Brian Kirmse; Tzy-Jyun Yao; Sean Hofherr; Deborah Kacanek; Paige L Williams; Charlotte V Hobbs; Rohan Hazra; William Borkowsky; Russell B Van Dyke; Marshall Summar
Journal:  AIDS Res Hum Retroviruses       Date:  2016-01-19       Impact factor: 2.205

7.  Neuropsychological Development in Patients with Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase (LCHAD) Deficiency.

Authors:  A Strandqvist; C Bieneck Haglind; R H Zetterström; A Nemeth; U von Döbeln; M Halldin Stenlid; A Nordenström
Journal:  JIMD Rep       Date:  2015-11-07

8.  Parent Coping and the Behavioural and Social Outcomes of Children Diagnosed with Inherited Metabolic Disorders.

Authors:  Amy Brown; Louise Crowe; Avihu Boneh; Vicki Anderson
Journal:  JIMD Rep       Date:  2016-03-24

9.  Inborn Errors of Long-Chain Fatty Acid β-Oxidation Link Neural Stem Cell Self-Renewal to Autism.

Authors:  Zhigang Xie; Albert Jones; Jude T Deeney; Seong Kwon Hur; Vytas A Bankaitis
Journal:  Cell Rep       Date:  2016-01-28       Impact factor: 9.423

Review 10.  Screening newborns for metabolic disorders based on targeted metabolomics using tandem mass spectrometry.

Authors:  Hye-Ran Yoon
Journal:  Ann Pediatr Endocrinol Metab       Date:  2015-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.